Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition
The Oncologist · 2026
DOI: 10.1093/oncolo/oyaf411 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Leon van Hout und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Amsterdam UMC, De Boelelaan 1117, Amsterdam, 1081HV, The Netherlands. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Antineoplastic Agents, Alkylating. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
Myelotoxicity is a well-known adverse effect of alkylating chemotherapy for glioblastoma. While risk factors during first-line therapy are established, little is known about myelotoxicity recurrence in second-line treatment. This study investigates whether first-line myelotoxicity therapy predisposes patients to recurrence in the second-line setting. Patients and Methods We conducted a retrospective cohort study of 589 patients with glioblastoma treated at the Brain Tumor Centre Amsterdam (2005-2022). Of these, 178 received second-line lomustine or rechallenge temozolomide. Myelotoxicity severity was predominantly assessed using nadir hematological values and its duration. A log-link generalized linear model evaluated associations between first-line and second-line myelotoxicity severity, adjusting for covariates. Cox proportional hazards models assessed time to myelotoxicity onset.
Results
We included 151 patients (mean age 57.1 ± 11.8 years; 66.9% male). Lomustine was given to 66.9%. Myelotoxicity occurred in 73.5% of patients, with 19.9% developing severe toxicity. First-line myelotoxicity severity was significantly associated with second-line severity (β = 1.3, P < .001). Lomustine correlated with higher myelotoxicity severity than temozolomide (β = 1.4, P = .002). Higher first-line myelotoxicity scores predicted earlier onset of any-grade (HR = 1.4, P < .001) and severe (HR =2.1, P < .001) myelotoxicity in second-line therapy.
Conclusion
First-line myelotoxicity for glioblastoma predicts its recurrence and earlier onset in second-line therapy. Patients with toxicity in first-line have an increased risk of severe hematological toxicity upon re-exposure. Lomustine carries a higher risk for myelotoxicity than temozolomide. These findings suggest an inherent predisposition to alkylating chemotherapy-induced myelotoxicity for a subgroup of patients. Integrating prior myelotoxicity history into second-line treatment decisions may improve risk stratification and guide monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Amsterdam UMC, De Boelelaan 1117, Amsterdam, 1081HV, The Netherlands.
- Department of Neurosurgery, Amsterdam UMC, Amsterdam, 1081HV, The Netherlands.
- Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, 1081HV, The Netherlands.
- Department of Neurology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, 6229ER, The Netherlands.
- Department of Clinical Pharmacy & Pharmacology, Amsterdam UMC, Amsterdam, 1081HV, The Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, 1081HV, The Netherlands.
ORCID-Profile: Leon van Hout, Jan Buter, Mathilde C M Kouwenhoven
Zitieren
APA
van Hout, L., van den Elzen, F. E. L., de Jong, Z., Grun, N., Broen, M. P. G., Bartelink, I., Bruynzeel, A. M. E., Lagerwaard, F. J., Buter, J., Vandertop, W. P., Westerman, B. A., Lissenberg-Witte, B. I., & Kouwenhoven, M. C. M. (2026). Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition. The Oncologist. https://doi.org/10.1093/oncolo/oyaf411
Vancouver
van Hout L, van den Elzen FEL, de Jong Z, Grun N, Broen MPG, Bartelink I, et al. Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition. The Oncologist. 2026. doi:10.1093/oncolo/oyaf411
BibTeX
@article{vanHout2026,
author = {van Hout, Leon and van den Elzen, Femke E L and de Jong, Zoë and Grun, Nienke and Broen, Martinus P G and Bartelink, Imke and Bruynzeel, Anna M E and Lagerwaard, Frank J and Buter, Jan and Vandertop, William Peter and Westerman, Bart A and Lissenberg-Witte, Birgit I and Kouwenhoven, Mathilde C M},
title = {Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyaf411}
}
EUVIMED